<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04605393</url>
  </required_header>
  <id_info>
    <org_study_id>IRAS: 278595</org_study_id>
    <nct_id>NCT04605393</nct_id>
  </id_info>
  <brief_title>Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study</brief_title>
  <acronym>INTEGRATE</acronym>
  <official_title>Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will recruit schizophrenia patients who use cannabis recreationally. Each&#xD;
      participant will attend the laboratory on three occasions: an initial visit to check that&#xD;
      they are safe to join the study and two days of testing.&#xD;
&#xD;
      Participants will be administered, in a randomized order, a pre-treatment with either CBD&#xD;
      (1000mg) orally or a matching placebo. On both experiments, participants will then inhale&#xD;
      cannabis containing THC. The THC administration will follow a standardised inhalation&#xD;
      procedure using a medical-grade vaporizer device.&#xD;
&#xD;
      Participants will complete a series of tasks measuring cognition, psychosis, anxiety and&#xD;
      other subjective experiences.&#xD;
&#xD;
      The study will be carried out at the NIHR-Wellcome Trust Clinical Research Facility at King's&#xD;
      College Hospital.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hopkins Verbal Learning Test</measure>
    <time_frame>Baseline; 25mins after THC inhalation</time_frame>
    <description>Delayed verbal recall</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hopkins Verbal Learning Test</measure>
    <time_frame>Baseline; 20 - 40 mins after THC inhalation</time_frame>
    <description>Immediate verbal recall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digit spain</measure>
    <time_frame>Baseline; 20 - 40 mins after THC inhalation</time_frame>
    <description>Forward &amp; Reverse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White Noise Task</measure>
    <time_frame>Baseline; 30-60 mins after THC inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Advice Taking Task</measure>
    <time_frame>Baseline; 30-60 mins after THC inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effort Expenditure for Rewards Task</measure>
    <time_frame>Baseline; 30-60 mins after THC inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale</measure>
    <time_frame>pre-CBD/placebo administration and 4 hours after THC inhalation</time_frame>
    <description>Positive Subscale &amp; Negative Subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State Social Paranoia Scale</measure>
    <time_frame>pre-CBD/placebo administration and 4 hours after THC inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State-Trait Anxiety Inventory</measure>
    <time_frame>pre-CBD/placebo administration, pre-THC/placebo inhalation and 90mins hours after THC inhalation</time_frame>
    <description>State Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study drug preference</measure>
    <time_frame>Experiment 2, 4 hours after THC/placebo inhalation</time_frame>
    <description>At the end of the final experimental visit, participants will be asked to order the two experimental visits according to which drug combination they found most pleasurable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scales</measure>
    <time_frame>-210mins, -120mins, -30mins, +10mins, +45mins, +90mins, +210mins</time_frame>
    <description>Feel drug effect&#xD;
Like drug effect&#xD;
Want more drug&#xD;
Thinking clearly&#xD;
Tired&#xD;
Excited&#xD;
Want to talk&#xD;
Anxious&#xD;
Relaxed&#xD;
Happy&#xD;
Irritable&#xD;
Suspicious&#xD;
Hearing voices&#xD;
Dry mouth&#xD;
Hungry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma delta-9-tetrahydrocannabinol (THC) concentration</measure>
    <time_frame>-210mins, -90mins, 0mins, 5mins, 15mins, +90mins from end of THC inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma cannabidiol (CBD) concentration</measure>
    <time_frame>-210mins, -90mins, 0mins, 5mins, 15mins, +90mins from end of THC inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma THC-COOH concentraion</measure>
    <time_frame>-210mins, -90mins, 0mins, 5mins, 15mins, +90mins from end of THC inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma 11-COOH-THC concentration</measure>
    <time_frame>-210mins, -90mins, 0mins, 5mins, 15mins, +90mins from end of THC inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma 11-OH-THC concentration</measure>
    <time_frame>-210mins, -90mins, 0mins, 5mins, 15mins, +90mins from end of THC inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma 6-OH-CBD concentration</measure>
    <time_frame>-210mins, -90mins, 0mins, 5mins, 15mins, +90mins from end of THC inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma anandamide concentration</measure>
    <time_frame>-210mins, -90mins, 0mins, 5mins, 15mins, +90mins from end of THC inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma 2-arachidonoylglycerol concentration</measure>
    <time_frame>-210mins, -90mins, 0mins, 5mins, 15mins, +90mins from end of THC inhalation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Cannabis Use</condition>
  <arm_group>
    <arm_group_label>Placebo/THC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral placebo followed by inhalation of cannabis containing THC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBD/THC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CBD 1000mg followed by inhalation of cannabis containing THC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <description>CBD</description>
    <arm_group_label>CBD/THC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo/THC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delta-9-THC</intervention_name>
    <description>THC</description>
    <arm_group_label>CBD/THC</arm_group_label>
    <arm_group_label>Placebo/THC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Age 18-65 years.&#xD;
&#xD;
          -  Clinical diagnosis of schizophrenia (i.e. documented as such in the patient's clinical&#xD;
             records and satisfying ICD-10 criteria for F20)&#xD;
&#xD;
          -  Clinically stable for at least three months (since discharge from hospital, home&#xD;
             treatment team, or prior clinical deterioration, and with agreement from the patient's&#xD;
             responsible clinician)&#xD;
&#xD;
          -  Regular (at least weekly) cannabis use for the past 3 months or more&#xD;
&#xD;
          -  Evidence from either clinicians or from the patient that cannabis use exacerbates&#xD;
             their symptoms or increases their risk of relapse&#xD;
&#xD;
          -  Treatment with regular doses of antipsychotic medication for at least 1 month,&#xD;
             confirmed by a blood test at the baseline visit, and with the participant agreeing to&#xD;
             be maintained at a stable dose over the course of the experiment&#xD;
&#xD;
          -  The participant agrees to abstain from cannabis use for at least 24hours prior to&#xD;
             study visits&#xD;
&#xD;
          -  The participant is willing to have an intravenous cannula inserted to collect blood&#xD;
             samples on experimental visits&#xD;
&#xD;
          -  Sufficiently fluent English&#xD;
&#xD;
          -  Providing written informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Extreme cannabis use: participant is estimate to be using over 1gram of cannabis/day&#xD;
&#xD;
          -  Dependence on alcohol or illicit substances other than cannabis as defined by ICD-10&#xD;
&#xD;
          -  Pregnancy (current or planned) or breastfeeding&#xD;
&#xD;
          -  Physical health disorder or another mental health disorder that the study psychiatrist&#xD;
             judges may influence the patient's ability to tolerate the procedure, or that may&#xD;
             alter the results of the study.&#xD;
&#xD;
          -  Taken part in any drug study within the last 3 months or taking part in another study&#xD;
             over the course of the trial&#xD;
&#xD;
          -  Drug sensitivity/allergy to cannabis or Lorazepam&#xD;
&#xD;
          -  Unlikely to be able to complete the study sessions for any reason, as judged by the&#xD;
             study psychiatrist&#xD;
&#xD;
        Additional criteria which must be met on experimental visits:&#xD;
&#xD;
          -  Negative alcohol breath test&#xD;
&#xD;
          -  Negative urine drug screen (apart from cannabis and prescribed medication)&#xD;
&#xD;
          -  Negative urine pregnancy test&#xD;
&#xD;
          -  Stable mental state as judged by the study psychiatrist&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gill Dale</last_name>
    <role>Study Chair</role>
    <affiliation>slam-ioppn.research@kcl.ac.uk</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edward Chesney</last_name>
    <phone>020 7848 0339</phone>
    <email>edward.chesney@kcl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gill Dale</last_name>
    <phone>020 7848 0339</phone>
    <email>slam-ioppn.research@kcl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>South London and Maudsley NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE58AZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Chesney</last_name>
    </contact>
    <investigator>
      <last_name>Edward Chesney</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 5, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King's College London</investigator_affiliation>
    <investigator_full_name>Dr Edward Chesney</investigator_full_name>
    <investigator_title>Psychiatrist/Clinical Research Fellow/Study Co-ordinator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
    <mesh_term>Cannabidiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 26, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT04605393/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

